

NDA 022076/S-006

SUPPLEMENT APPROVAL

Bausch Health U.S., LLC
Attention: Sahana Turuvekere
Senior Regulatory Affairs Specialist
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807

Dear Sahana Turuvekere:

Please refer to your supplemental new drug application (sNDA) dated June 22, 2018, received June 22, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Locoid (hydrocortisone butyrate) lotion 0.1%.

This Prior Approval sNDA provides for a Pregnancy and Lactation Labeling Rule (PLLR) revision to the approved labeling.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

- 1) **HIGHLIGHTS OF PRESCRIBING INFORMATION** section
 - a. Update the **Revised** date to 10/2023.
- 2) **2 Dosage and Administration** section
 - a. In the first bullet, change “lotion” to “Lotion”.
 - b. In the second bullet, delete the period before the cross reference: “reactions: [see *Warnings and Precautions (5.1)*, *Adverse Reactions (6.1, 6.2)*].”
- 3) **8 USE IN SPECIFIC POPULATIONS** section
 - a. Change the font and font size of “*Animal Data*” to Times New Roman, 11 pt.
 - b. Change the font size of “**8.2 Lactation**” to 12 pt.
 - c. Delete the letter “n” in the second sentence of the **8.4 Pediatric Use** section: “Use of LOCOID Lotion for this indication ~~is~~ supported by evidence from an adequate and well-controlled trial in 284 pediatric patients 3 months to 18 years of age with mild to moderate atopic dermatitis.”

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email me at Howard.VanHornIII@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tatiana Oussova, MD, MPH
Deputy Director for Safety
Division of Dermatology and Dentistry
Office of Immunology and Inflammation
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S): Content of Labeling

- Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TATIANA OUSSOVA
10/18/2023 10:50:47 AM